A randomized, double-blind, placebo-controlled, dose-escalating phase IIa trial to evaluate the safety, tolerability, efficacy, and pharmacokinetics of multiple oral doses of Pynegabine tablets as add-on therapy in patients with focal epilepsy.

Shan WeiWeng ShiwenChang Cao-WenjingYang HuajunWang Qun

Published in: CNS neuroscience & therapeutics (2024)

Data from the study will be used to evaluate the safety, tolerability, efficacy, and pharmacokinetics of Pynegabine tablets as add-on therapy for focal epilepsy.

Keyphrases

placebo controlled
double blind
phase iii
phase ii
study protocol
clinical trial
open label
phase ii study
randomized controlled trial
electronic health record
big data
temporal lobe epilepsy
artificial intelligence
replacement therapy
cell therapy
data analysis
rectal cancer